NasdaqGS:REGN

Stock Analysis Report

Executive Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide.

Snowflake

Fundamentals

Flawless balance sheet and fair value.


Similar Companies

Share Price & News

How has Regeneron Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.1%

REGN

1.0%

US Biotechs

-0.6%

US Market


1 Year Return

-24.2%

REGN

-10.8%

US Biotechs

0.7%

US Market

REGN underperformed the Biotechs industry which returned -10.8% over the past year.

REGN underperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

REGNIndustryMarket
7 Day5.1%1.0%-0.6%
30 Day0.3%0.3%2.9%
90 Day-7.6%-1.1%1.3%
1 Year-24.2%-24.2%-10.1%-10.8%2.9%0.7%
3 Year-27.9%-27.9%5.8%2.2%44.6%35.2%
5 Year-17.4%-17.4%3.7%-1.3%61.9%44.2%

Price Volatility Vs. Market

How volatile is Regeneron Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

2 weeks ago | Simply Wall St

Have Insiders Been Selling Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares?

Valuation

Is Regeneron Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

24%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Regeneron Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).

Regeneron Pharmaceuticals's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Regeneron Pharmaceuticals is good value based on earnings compared to the US Biotechs industry average.

Regeneron Pharmaceuticals is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Regeneron Pharmaceuticals is poor value based on expected growth next year.


Price Based on Value of Assets

Regeneron Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Regeneron Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 19 analysts?

8.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Regeneron Pharmaceuticals's revenue is expected to grow by 6.1% yearly, however this is not considered high growth (20% yearly).

Regeneron Pharmaceuticals's earnings are expected to grow by 8.1% yearly, however this is not considered high growth (20% yearly).

Regeneron Pharmaceuticals's revenue growth is positive but not above the United States of America market average.

Regeneron Pharmaceuticals's earnings growth is positive but not above the United States of America market average.

Regeneron Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Regeneron Pharmaceuticals is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).


Next Steps

Past Performance

How has Regeneron Pharmaceuticals performed over the past 5 years?

37.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Regeneron Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.

Regeneron Pharmaceuticals's 1-year earnings growth is less than its 5-year average (30% vs 37.8%)

Regeneron Pharmaceuticals's earnings growth has not exceeded the US Biotechs industry average in the past year (30% vs 78.4%).


Return on Equity

Regeneron Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

Regeneron Pharmaceuticals used its assets more efficiently than the US Biotechs industry average last year based on Return on Assets.


Return on Capital Employed

Regeneron Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Regeneron Pharmaceuticals's financial position?


Financial Position Analysis

Regeneron Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Regeneron Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Regeneron Pharmaceuticals has no debt.

Regeneron Pharmaceuticals has no debt compared to 5 years ago when it was 11.9%.

Regeneron Pharmaceuticals has no debt, it does not need to be covered by operating cash flow.

Regeneron Pharmaceuticals has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Regeneron Pharmaceuticals has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Regeneron Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Regeneron Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Regeneron Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Regeneron Pharmaceuticals has not reported any payouts.

Unable to verify if Regeneron Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Regeneron Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Regeneron Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Regeneron Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

3.1yrs

Average management tenure


CEO

Schleifer Leonard S. (66yo)

31.7yrs

Tenure

US$26,520,555

Compensation

Dr. Schleifer Leonard S., M.D., Ph.D. founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988. Dr. Schleifer served as the Chairman of Regeneron Ph ...


CEO Compensation Analysis

Schleifer's remuneration is higher than average for companies of similar size in United States of America.

Schleifer's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.1yrs

Average Tenure

59yo

Average Age

The tenure for the Regeneron Pharmaceuticals management team is about average.


Board Age and Tenure

21.7yrs

Average Tenure

68.5yo

Average Age

The average tenure for the Regeneron Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$48,611,80412 Sep 19
Sanofi
EntityCompany
Shares172,904
Max PriceUS$281.15
SellUS$305,93016 May 19
Joseph Goldstein
EntityIndividual
Role
Member of the Board of Directors
Director
Shares1,000
Max PriceUS$305.93
SellUS$54,041,31613 Mar 19
Sanofi
EntityCompany
Shares131,115
Max PriceUS$412.17
SellUS$2,29414 Dec 18
Pindaros Vagelos
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares6
Max PriceUS$382.32

Ownership Breakdown


Management Team

  • Schleifer Leonard S. (66yo)

    Co-Founder

    • Tenure: 31.7yrs
    • Compensation: US$26.52m
  • George Yancopoulos (59yo)

    Founding Scientist

    • Tenure: 18.7yrs
    • Compensation: US$25.38m
  • Joe LaRosa (60yo)

    Executive VP

    • Tenure: 8yrs
    • Compensation: US$3.38m
  • Marion McCourt (59yo)

    Senior VP & Head of Commercial

    • Tenure: 1.6yrs
    • Compensation: US$10.28m
  • Bob Landry (55yo)

    Executive VP of Finance & CFO

    • Tenure: 5.9yrs
    • Compensation: US$9.36m
  • Beth Levine (55yo)

    Senior VP

    • Tenure: 0.7yrs
  • Daniel Van Plew (46yo)

    Executive VP and GM of Industrial Operations & Product Supply

    • Tenure: 11.4yrs
    • Compensation: US$9.01m
  • Sally Paull

    Senior Vice President of Human Resources

    • Tenure: 3.4yrs
  • Hala Mirza

    Senior Vice President of Corporate Communications & Citizenship

    • Tenure: 0.7yrs
  • Justin Holko

    Vice President of Investor Relations

    • Tenure: 0.3yrs

Board Members

  • Chris Poon (67yo)

    Director

    • Tenure: 8.8yrs
    • Compensation: US$1.23m
  • Pindaros Vagelos (89yo)

    Chairman of the Board

    • Tenure: 24.7yrs
    • Compensation: US$6.35m
  • Schleifer Leonard S. (66yo)

    Co-Founder

    • Tenure: 31.7yrs
    • Compensation: US$26.52m
  • George Yancopoulos (59yo)

    Founding Scientist

    • Tenure: 18.7yrs
    • Compensation: US$25.38m
  • Art Ryan (76yo)

    Director

    • Tenure: 16.7yrs
    • Compensation: US$1.23m
  • Michael Brown (78yo)

    Director

    • Tenure: 28.3yrs
    • Compensation: US$1.23m
  • Joseph Goldstein (79yo)

    Director

    • Tenure: 28.3yrs
    • Compensation: US$1.22m
  • George Sing (70yo)

    Director

    • Tenure: 31.7yrs
    • Compensation: US$1.23m
  • Marc Tessier-Lavigne (59yo)

    Director

    • Tenure: 7.8yrs
    • Compensation: US$1.21m
  • Bonnie Bassler (57yo)

    Director

    • Tenure: 3yrs
    • Compensation: US$1.22m

Company Information

Regeneron Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Regeneron Pharmaceuticals, Inc.
  • Ticker: REGN
  • Exchange: NasdaqGS
  • Founded: 1988
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$32.375b
  • Shares outstanding: 109.42m
  • Website: https://www.regeneron.com

Number of Employees


Location

  • Regeneron Pharmaceuticals, Inc.
  • 777 Old Saw Mill River Road
  • Tarrytown
  • New York
  • 10591
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
REGNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 1991
RGODB (Deutsche Boerse AG)YesCommon StockDEEURApr 1991
REGNSWX (SIX Swiss Exchange)YesCommon StockCHCHFApr 1991
0R2MLSE (London Stock Exchange)YesCommon StockGBUSDApr 1991
REGN *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNApr 1991
REGNWBAG (Wiener Boerse AG)YesCommon StockATEURApr 1991
REGN34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 1 REP 0.2 COM USD0.001BRBRLMay 2019

Biography

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s produ ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 23:43
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.